Structure-based drug discovery has become a key enabler of innovation in modern pharmaceutical research, offering a rational framework for the design and optimization of new therapeutics. By revealing how drug molecules interact with their biological targets at the atomic level, structural insight provides a powerful foundation for informed decision-making throughout the discovery process. This session will highlight how both experimental and computational methods contribute to this effort, from structural biology techniques that uncover target architecture and ligand binding modes to in silico approaches that support modeling, prediction, and design. Together, these complementary strategies help guide medicinal chemistry, accelerate lead optimization, and improve the progression from target identification to high-quality drug candidates. By integrating experimental data with computational insight, structure-based drug discovery enables more efficient discovery pathways and ultimately supports the development of safer and more effective medicines.